Michael Mortensen

Chief Operating Officer presso BONESUPPORT HOLDING AB

Patrimonio netto: 828 085 $ in data 31/03/2024

Consumer Services

Health Technology

Profilo

Michael Wrang Mortensen is currently the Director of Development & Supply at Nanovi Radiotherapy A and the EVP of Research, Development & Operations at BONESUPPORT HOLDING AB.
He has a graduate degree from the Technical University of Denmark, a doctorate from the University of Copenhagen, and an MBA from AVT Business School A.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
BONESUPPORT HOLDING AB 0.06%	05/03/2024	38 835 ( 0.06% )	828 085 $	31/03/2024

Posizioni attive di Michael Mortensen

Società	Posizione	Inizio
BONESUPPORT HOLDING AB	Chief Operating Officer	01/12/2021
Nanovi Radiotherapy A/S Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark.	Corporate Officer/Principal	-

Tutte le posizioni attive di Michael Mortensen

Formazione di Michael Mortensen

Technical University of Denmark	Graduate Degree
University of Copenhagen	Doctorate Degree
AVT Business School A/S	Masters Business Admin

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Michael Mortensen

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
BONESUPPORT HOLDING AB	Health Technology

Aziende private	1
Nanovi Radiotherapy A/S Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark.	Health Technology